QAASM: an evaluation of three methods of external quality assurance for patient self-management of oral anticoagulation

Submission date Recruitment status Prospectively registered 11/02/2003 No longer recruiting [] Protocol [] Statistical analysis plan Registration date Overall study status 11/02/2003 Completed [X] Results [] Individual participant data Last Edited Condition category Haematological Disorders 15/08/2008

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Ms Ellen Murray

Contact details

Department of Primary Care and General Practice University of Birmingham Edgbaston United Kingdom B15 2TT +44 (0)121 414 3761 e.t.murray@bham.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers G106/970

Study information

Scientific Title

Acronym

QAASM

Study objectives

Aim:

To evaluate three different methods of external quality assurance (EQA) for home management.

Primary objective:

To compare patients' treatment related quality of life in relation to external quality assurance for home anticoagulation management, with or without supervision.

Secondary objective:

To compare three different methods of EQA, one unsupervised and two supervised in terms of:

- 1. Reliability of EQA results
- 2. Impact on international normalised ratio (INR) control
- 3. Costs associated with each method of EQA

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Anticoagulant therapy

Interventions

Patients from the SMART trial (Self-management of warfarin: a randomised trial) will be randomly allocated to two main groups at practice level for supervised or non-supervised External Quality Control (EQA). Twenty-four practices into groups 1 and 2.

The practices randomised to supervised EQA will then be further randomly allocated to different methods of supervised EQA, Groups 2A and 2B.

Unsupervised group: formal EQA scheme (National Quality Assessment Scheme NEQAS).

Supervised groups: International normalised ratio (INR) results from venous samples sent to the local laboratory will be compared with contemporaneous near patient testing (NPT) capillary samples at the practice using the patient's NPT system, or INR results from patient NPT system capillary sample tests will be compared to results from an NPT system weekly quality control tested using samples from NEQAS at the practice, NPT to NPT.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Difference in treatment related quality of life scores between non supervised and supervised EOA models

Secondary outcome measures

- 1. Comparison of EQA results between three models of EQA
- 2. Comparison of therapeutic INR control in terms of the percentage of time spent within therapeutic range
- 3. Cost comparison of EQA models

Overall study start date

01/08/2000

Completion date

31/07/2004

Eligibility

Key inclusion criteria

- 1. Patients aged 18 or over
- 2. A long term (greater than 12 months) indication for oral anticoagulation
- 3. Have taken warfarin for at least six months
- 4. Are willing (or in the case of dependent patients both they and their carer are willing) to participate in the study

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

260

Key exclusion criteria

- 1. Patients with a short-term indication (less than 12 months) for warfarin therapy
- 2. Aged under 18 years
- 3. Housebound patients
- 4. Patients confined to a nursing home

Date of first enrolment

01/08/2000

Date of final enrolment

31/07/2004

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Department of Primary Care and General Practice

Edgbaston United Kingdom B15 2TT

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Sponsor details

20 Park Crescent London United Kingdom W1B 1AL +44 (0)20 7636 5422 clinical.trial@headoffice.mrc.ac.uk

Sponsor type

Research council

Website

http://www.mrc.ac.uk

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (MRC) (UK) - Special Training Fellowship in HSR

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/11/2002		Yes	No